Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company specializing in clinical trial matching. This strategic move aims to enhance Tempus’ ...

The deal also brings integration and execution risks. Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market ...

Adjusted EBITDA for 2025: Expected to be approximately $5 million. Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years.

CHICAGO, February 03, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

For this year, Tempus AI, Inc. (NASDAQ:TEM) expects full-year revenue of approximately $1.24 billion for the consolidated TEM and Ambry Genetics business, which represents approximately 79 percent ...